Literature DB >> 30175481

Immune function of plasmacytoid dendritic cells, natural killer cells, and their crosstalk in HBV infection.

Forough Golsaz-Shirazi1, Mohammad Mehdi Amiri1, Fazel Shokri1,2.   

Abstract

Chronic hepatitis B virus infection is a major health problem, with over 245 million chronic carriers worldwide. This persistent infection is thought to be associated with inefficient innate and adaptive immune responses. Natural killer cells (NK cells) and plasmacytoid dendritic cells (pDCs) are the major innate immune cells which respond to viral infection at the early phase and are considered major components of the antiviral immune response. In this review, we summarize recent findings regarding the role of NK cells, pDCs, and their cross-talk in HBV infection and its chronicity. Although the data regarding the biological function of pDCs and NK cells in HBV infection is still controversial, many studies show that in chronic HBV infection, the cytotoxicity of NK cells is retained, while their capacity to secrete cytokines is strongly impaired. In addition, interferon-α production by pDCs is impaired during chronic HBV infection, and the virus interferes with pDC-NK cell interaction.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  HBV infection; natural killer cells; plasmacytoid dendritic cells

Mesh:

Substances:

Year:  2018        PMID: 30175481     DOI: 10.1002/rmv.2007

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  8 in total

1.  Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients.

Authors:  Minghui Li; Luxue Zhang; Si Xie; Fangfang Sun; Zhan Zeng; Wen Deng; Tingting Jiang; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Ge Shen; Ruyu Liu; Shuling Wu; Min Chang; Leiping Hu; Jianping Dong; Wei Yi; Yao Xie
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

2.  Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment.

Authors:  Weihua Cao; Si Xie; Lu Zhang; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Ruyu Liu; Min Chang; Shuling Wu; Ge Shen; Jianping Dong; Yao Xie; Minghui Li
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

3.  Increase in liver γδ T cells with concurrent augmentation of IFN-β production during the early stages of a mouse model of acute experimental hepatitis B virus infection.

Authors:  Lin Chang; Lei Wang; Ning Ling; Hui Peng; Min Chen
Journal:  Exp Ther Med       Date:  2019-11-13       Impact factor: 2.447

4.  The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy.

Authors:  Weihua Cao; Minghui Li; Lu Zhang; Yao Lu; Shuling Wu; Ge Shen; Min Chang; Ruyu Liu; Yuanjiao Gao; Hongxiao Hao; Leiping Hu; Wei Yi; Calvin Q Pan; Yao Xie
Journal:  Biomed Res Int       Date:  2021-01-25       Impact factor: 3.411

5.  B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy.

Authors:  Zhenhuan Cao; Sha Meng; Yanhong Zheng; Junli Wang; Rui Wang; Xinyue Chen
Journal:  PLoS One       Date:  2020-12-02       Impact factor: 3.240

6.  Mapk14 is a Prognostic Biomarker and Correlates with the Clinicopathological Features and Immune Infiltration of Colorectal Cancer.

Authors:  Dan Wang; Li Peng; Li Hua; Jiaxiang Li; Yifei Liu; Yanhong Zhou
Journal:  Front Cell Dev Biol       Date:  2022-01-24

Review 7.  Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection.

Authors:  Yanqin Du; Jun Wu; Jia Liu; Xin Zheng; Dongliang Yang; Mengji Lu
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

Review 8.  The Role of Dendritic Cells During Infections Caused by Highly Prevalent Viruses.

Authors:  Jorge A Soto; Nicolas M S Gálvez; Catalina A Andrade; Gaspar A Pacheco; Karen Bohmwald; Roslye V Berrios; Susan M Bueno; Alexis M Kalergis
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.